Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER2-low breast cancers: Current insights and future directions.
Zhang H, Karakas C, Tyburski H, Turner BM, Peng Y, Wang X, Katerji H, Schiffhauer L, Hicks DG. Zhang H, et al. Among authors: schiffhauer l. Semin Diagn Pathol. 2022 Sep;39(5):305-312. doi: 10.1053/j.semdp.2022.07.003. Epub 2022 Jul 9. Semin Diagn Pathol. 2022. PMID: 35872032 Review.
Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression.
Banerjee S, Lin CF, Skinner KA, Schiffhauer LM, Peacock J, Hicks DG, Redmond EM, Morrow D, Huston A, Shayne M, Langstein HN, Miller-Graziano CL, Strickland J, O'Donoghue L, De AK. Banerjee S, et al. Among authors: schiffhauer lm. Cancer Res. 2011 Jan 15;71(2):318-27. doi: 10.1158/0008-5472.CAN-10-1778. Epub 2011 Jan 11. Cancer Res. 2011. PMID: 21224361
Significance of HER2 in Microinvasive Breast Carcinoma.
Zhang H, Moisini I, Turner BM, Wang X, Dhakal A, Yang Q, Kovar S, Schiffhauer LM, Hicks DG. Zhang H, et al. Among authors: schiffhauer lm. Am J Clin Pathol. 2021 Jun 17;156(1):155-165. doi: 10.1093/ajcp/aqaa222. Am J Clin Pathol. 2021. PMID: 33491064
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing.
Turner BM, Finkelman BS, Hicks DG, Numbereye N, Moisini I, Dhakal A, Skinner K, Sanders MAG, Wang X, Shayne M, Schiffhauer L, Katerji H, Zhang H. Turner BM, et al. Among authors: schiffhauer l. Cancers (Basel). 2023 Jan 31;15(3):903. doi: 10.3390/cancers15030903. Cancers (Basel). 2023. PMID: 36765860 Free PMC article.
20 results